Nabriva Gains New CEO And Near-Market Antibiotic, Claims Leadership Role

 
• By John Davis

The acquisition of Zavante Therapeutics and its late-stage investigational intravenous antibiotic for use in multi-drug resistant pathogens has also led to C-suite change at Nabriva Therapeutics.

SC1807_Tracks-Merged_335693570_1200.jpg
The acquisition will merge the product pipeline of the two companies. • Source: Shutterstock

More from Deals

More from Business